A 45-year-old matched unrelated BMT recipient had sequential mucocutaneous herpes simplex virus (HSV) type 2 infections. Five months after BMT, a penile lesion occurred and was cured using acyclovir, as expected from in vitro susceptibility results. The same lesion recurred 1 month later but worsened with acyclovir. The HSV isolate was resistant to acyclovir (IC 50 = 105 M), and a nucleotide (G) was added to the thymidine kinase gene leading to a premature stop codon. The lesion improved markedly with foscarnet. During this treatment a second HSV infection occurred on the buttocks 2 weeks after the first one and healed completely with acyclovir. This course correlated with in vitro results of the buttock HSV isolate which was foscarnetresistant (IC 50 = 300 g/ml) and acyclovir-sensitive. Surprisingly, no mutation gene of the foscarnet-resistant isolate was detected in the DNA polymerase gene. This case shows that an HSV acyclovir-resistant infection may be followed by an acyclovir-sensitive one. Determination of antiviral susceptibility is needed to monitor the treatment of various HSV infections in immunocompromised BMT recipients. Bone Marrow Transplantation (2001) 28, 799-801. Keywords: herpes simplex virus; acyclovir; foscarnet; resistance; bone marrow transplantation Despite the wide use of acyclovir (ACV) prophylaxis, herpes simplex virus (HSV) infections or reactivations remain a major cause of morbidity in patients who have undergone allogenic bone marrow transplantation (BMT). One of the most widely used explanations is the occurrence of acyclovir resistance in a severely immunocompromised host.
Despite the wide use of acyclovir (ACV) prophylaxis, herpes simplex virus (HSV) infections or reactivations remain a major cause of morbidity in patients who have undergone allogenic bone marrow transplantation (BMT). One of the most widely used explanations is the occurrence of acyclovir resistance in a severely immunocompromised host. 1 The loss of ACV sensitivity is frequently associated with an impairment of viral thymidine kinase (TK), and successful treatment of ACV-resistant HSV infection may result with alternative agents such as foscarnet, a pyrophosphate analogue that directly inhibits viral DNA polymerase (pol), and was first used in patients with AIDS. 2 However, foscarnet is also increasingly used for the treatment of CMV infections, and resistance due to DNA polymerase (DNA pol) mutations have emerged. 3 We describe the successive occurrence of recurrent mucocutaneous HSV2 infections with a different pattern of antiviral drug sensitivity depending on the site of infection. This case report demonstrates that in vitro susceptibility to antiviral agents is needed to monitor HSV infection treatment in severely immunosuppressed hosts.
Methods
Determination of in vitro susceptibility was performed using a plaque reduction assay.
2 Acyclovir resistance was defined by 50% inhibitory concentration (IC 50 ) values у2 g/ml (7.6 m) and foscarnet-resistance was defined by a three-fold increase in IC 50 values compared with those of a pretherapy isolate from the same patient. 2 Sense and nonsense strands of the viral TK gene (1.2 kb) were amplified and sequenced as reported elsewhere. 4 The entire DNA pol gene (UL 30) was amplified with primers: 5Ј-ACCACACACTGGCTCTCG-3Ј (forward) and 5Ј-ATACGATCTTTGAGCACCGC-3Ј (reverse). PCR products were directly sequenced using the dye terminator assay and an automated sequencer (ABI sequencer). TK sequences and the DNA pol of a resistant isolate were compared with the susceptible isolates and a reference strain available from GenBank.
Case report
A 45-year-old man who had been under treatment for 18 months for chronic myeloid leukemia received a bone marrow transplant from a matched unrelated donor. Treatment prior to BMT consisted of hydroxyurea, followed by interferon plus cytarabine which led to a minor cytogenetic response. The BMT was performed in October 1996 from a mismatched unrelated donor, with a conditioning regimen of cyclophosphamide and total body irradiation. Cyclosporin (3 mg/kg) and methotrexate (days 1, 3 and 6) were given as graft-versus-host disease (GVHD) prophylaxis ( Figure  1 ). Acyclovir prophylaxis 250 mg three times a day was given intravenously. One month after BMT the patient developed serious cutaneous and gastrointestinal GVHD (grade III-IV). He was treated with high doses of steroids, and then with antilymphocyte globulin resulting in regression of the GVHD. Steroids and cyclosporin were continued. One week later a cytomegalovirus infection was detected and the patient received ganciclovir for 3 weeks; the treatment was then switched to foscarnet until 3 months after BMT because of major myelotoxicity related to the ganciclovir. The first site of HSV2 infection, a penile ulcer, appeared 5 months after BMT. Treatment with acyclovir 10 mg/kg three times a day was initiated. The penile lesion slowly improved and the acyclovir was continued as secondary prophylaxis at an 800 mg daily dosage. One month later the lesion recurred at the same site. Despite administration of a high dose of acyclovir, no effect was observed and the lesion became more painful. However, when treatment with foscarnet (180 mg/kg/day) was started there was a dramatic improvement in the penile HSV lesion, but 10 days after the start of foscarnet an ulcerating lesion of the right buttock appeared, and viral analysis showed HSV2 lesion. Foscarnet was stopped because the genital lesion had healed. Acyclovir was then administered, leading to partial healing of the buttock lesion. Reactivation of the herpetic infection did not occur. However, the patient died 5 months later from severe bacterial pulmonary infection. Clinical features and virological results are summarized in Figure 1 .
Discussion
We describe a patient with multiple mucocutaneous HSV2 infections which occurred sequentially and displayed different antiviral resistance patterns. The recurrent first lesion was acyclovir-resistant but foscarnet-sensitive while the second was foscarnet-resistant but successfully treated with acyclovir. In vitro characterization susceptibility of HSV isolates was closely related to the clinical courses of the HSV infections. Acylovir-resistant HSV infection has been reported in 5 to 8% of bone marrow transplant patients 1, 5 but little is known about the course of acyclovir susceptibility in the same patient. Foscarnet resistance had been rare, but has recently emerged. [6] [7] [8] Such sequential and varying antiviral susceptibility patterns have not previously been reported in the same bone marrow transplant patient.
Reactivation of latent HSV infections is a frequent cause of morbidity following bone marrow transplantation, GVHD grade у2 recently being reported as a risk factor. 9 In the case reported here, consecutive HSV reactivations occurred more than 5 months after bone marrow transplantation. This late occurrence may reflect the profound immunodeficient state of the patient due to a prolonged period of steroid therapy and profound immunosuppressive action of ATG. The patient experienced CMV reactivation 1 month after BMT leading to treatment with ganciclovir followed by preventive treatment with foscarnet for 1 month. This treatment may have led to the development of foscarnet resistance. Acyclovir prophylaxis may also have facilitated the emergence of a resistant strain especially as it was given orally at a suboptimal dose due to a concern about immunosuppression.
In this case, two different strains with different antiviral sensitivities occurred in the same patient. In vitro analysis showed that the acyclovir-resistant lesion of the penis correlated with genotypic analysis. The mutation in the thymidine kinase gene consisted of the insertion of an additional G in homopolymer run of G which is in accordance with previous reports. 10 In contrast, study of the foscarnet-resistant HSV isolated from the buttocks lesion detected no change in the DNA polymerase gene. Two hypotheses can be proposed to explain this result. On the one hand, it may be due to the absence of amplification of a minor mutated population among wild-type strains. On the other hand, a double-stranded DNA-binding protein (UL 42) implicated in the increasing efficiency of DNA polymerase could have mutated leading to reduced efficiency of replication.
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In conclusion, antiviral susceptibility determination has been useful in monitoring these successive HSV infections. Indeed, in this patient, results have shown a difference of resistance patterns between the two strains of HSV isolated during a short period. The HSV buttock lesion was cidofovir and acyclovir susceptible in vitro. Although cidofovir could have been an alternative treatment for this lesion, 8 acyclovir was preferred because of the side-effects of cidofovir. Thus, acyclovir therapy was able to heal a second lesion located elsewhere since one HSV acyclovir-resistant lesion may be followed by an acyclovir-sensitive one.
